BayMed Venture Partners

BayMed Venture Partners is a venture capital investment firm based in San Francisco, California, founded in 2020. The firm specializes in investing in early-stage companies within the medical device and digital health sectors, focusing primarily on opportunities in North America and Israel. BayMed Venture Partners aims to support innovative solutions that can enhance healthcare delivery and improve patient outcomes.

Gary Gershony

Founding General Partner

Neil Meyer

Founding General Partner

2 past transactions

AtaCor Medical

Series C in 2024
AtaCor Medical, Inc. is a medical device company based in San Clemente, California, specializing in innovative solutions for cardiac pacing and rhythm management. Founded in 2014, the company has developed the AtaCor EV Temporary Pacing System, which allows for temporary pacing through a parasternal approach. This system advances a custom pacing lead into the extracardiac tissue between the ribs and pericardium, effectively restoring cardiac rhythm without the need for traditional pacing leads or hardware that typically attach directly to the heart. By facilitating quick deployment of temporary or emergency pacing therapy, AtaCor Medical addresses critical needs in cardiac care.

Deep Blue Medical Advances

Series A in 2022
Deep Blue Medical Advances, Inc. is a medical device manufacturer specializing in hernia repair solutions. Founded in 2015 and headquartered in Durham, North Carolina, with an additional office in San Francisco, the company develops innovative surgical devices, including its T-LineĀ® hernia mesh and anchor clips. These products are designed to address the high rates of hernia occurrence and recurrence, which pose significant clinical challenges and costs. The T-Line mesh features integral suture-like extensions to enhance fixation strength at the tissue interface, thereby reducing the risk of mesh failure. Additionally, the Anchor Clip fixation device facilitates quicker and more efficient implantation of the mesh. By improving surgical outcomes and patient experiences, Deep Blue Medical Advances aims to make a substantial impact within the $1.1 billion global hernia device market.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.